Group items tagged

Pharmaceutical giant GlaxoSmithKline aims to get its respiratory syncytial virus (RSV) vaccine to regulators for review later this year, after interim data showed the vaccine was effective in a keenly-watched late-stage study involving older adults. RSV is a leading cause of pneumonia in toddlers and the elderly, but the complex molecular structure of the virus and safety concerns have stymied efforts to develop a vaccine since the virus was first discovered in 1956. Companies including Pfizer, J&J, Sanofi, Moderna and AstraZeneca are also racing to get an RSV therapy or vaccine approved. The latest GSK trial is the first to show statistically significant efficacy for RSV in adults aged 60 years and older, the British drugmaker said of the ongoing study on Friday (June 10). If approved, the RSV vaccine is expected to generate billions for GSK, which is already the world's biggest vaccine maker by sales but has faced pressure from activist investors such as Elliott Management who have urged the London-based company to shore up its drug pipeline.

The rising epidemic of Ebola in Africa is a big reason to worry. The media coverage for this illness has not proved to be of much help. There is no possible Ebola virus cure in Ayurveda, but one can prevent it by keeping the body and immune system strong.

The rising epidemic of Ebola in Africa is a big reason to worry. The media coverage for this illness has not proved to be of much help. There is no possible Ebola virus cure in Ayurveda, but one can prevent it by keeping the body and immune system strong.

Here are the things you wanted to know about Zika Virus and Zika Fever. How the virus spreads, signs & symptoms, and possible protection against Zika.

Britain has become the first country to approve a Codiv-19 vaccine that targets both the original and Omicron variant of the virus. Medicines regulator MHRA approved the so-called bivalent vaccine made by US drug company Moderna as a booster for adults. The agency's decision was based on clinical trial data that showed the booster triggered "a strong immune response" against both Omicron (BA.1) and the original 2020 virus, it said. The MHRA also cited an exploratory analysis in which the shot was also found to generate a good immune response against the currently dominant Omicron offshoots BA.4 and BA.5. "The first generation of Covid-19 vaccines being used in the UK continue to provide important protection against the disease and save lives," MHRA chief executive June Raine said in a statement. "What this bivalent vaccine gives us is a sharpened tool in our armoury to help protect us against this disease as the virus continues to evolve."

The flu is an acute infectious disease of viral etiology. Flu symptoms are fever, cough, headache and muscle aches. It spreads easily from person to person, it circulates around the world and can affect everyone - from the youngest to the elderly and cause epidemics and pandemics. Disease known since ancient times. There is evidence that humanity has experienced so far over 30 flu pandemics, and only in the last century, there were three. The most serious of these, so called. "Spanish flu", founded in 1918, has led to the deaths of 20-50 million people. The flu virus belongs to the family Orthomyxoviridae, that there is only one race - Influenzavirus, including viruses causing disease in humans, mammals and birds. Some flu strains are species specific (infect only certain species, or only the people), but there are strains of flu that can spread from animal species to humans. Famous 3 types of flu virus - type A, type B and C. Influenza type C viruses, although similar in morphology differs from the other two types of the antigen and other basic properties. Influenza C occurs sporadically and causes respiratory disease with a slight leakage. Viruses that cause seasonal epidemics are of type A and type B. The most volatile are type A flu virus

Frontline doctors have sounded the alarm over the rising pressure on emergency departments in hospitals across the country as winter virus cases are "creeping up". An average of 234 people were in hospital with flu every day last week, a 53 per cent increase compared to the week before, according to new NHS data. Hospital norovirus cases increased by 15 per cent last week, with an average 406 people hospitalised each day, a 28 per cent increase from the same week last year. Measures to stop the spread of norovirus to other patients led to the closure of an average of 92 beds were closed each day last week.

Deaths caused by hepatitis C has declined by 35 per cent in England between 2015 and 2020, latest data from the UK Health Security Agency (UKHSA) revealed. It showed that estimated prevalence of chronic hepatitis C in England has continued to fall to around 81,000 in 2020 from 129,000 in 2015, showing a considerable progress has been made towards eliminating the virus as a public health problem by 2030 in England. Commenting on the data release, health and social care secretary Sajid Javid, said: "It is fantastic to see the significant progress that has been made in eliminating hepatitis C in England. Deaths and prevalence of the virus have fallen consistently thanks to improvements in diagnosis, access to treatments and the hard work of the NHS. "This is another example of the UK being at the forefront of tackling serious diseases. We are on track to eliminate this virus by 2030 and I urge anyone who may be at risk to get tested as soon as possible."

The UK Health Security Agency (UKHSA) and The Pirbright Institute have launched a new collaboration to develop vaccines against henipavirus, a genus of viruses that includes Nipah virus. Funded by the Medical Research Council, this research aims to develop a vaccine that provides cross protection against the whole genus, addressing the threat of outbreaks from new or emerging henipaviruses and strengthening epidemic preparedness. Scientists at UKHSA will evaluate the protective efficacy of vaccines developed by The Pirbright Institute by using use a model of Nipah virus disease, which mimics the infection in humans. Professor Isabel Oliver, chief scientific officer at UKHSA, stated that the study would improve understanding of henipaviruses and enhance efforts to protect health from this "current and future global health threat." "The work will also make a vital contribution to the 100 Days Mission - an important initiative to make sure the world is better prepared for the next pandemic by accelerating the development of diagnostics, therapeutics and vaccines," he added.

Khám phụ khoa arrow Bệnh xã hội arrow Bệnh sùi mào gà arrow Sùi mào gà hậu môn Sùi mào gà hậu môn Quan hệ tình dục không an toàn là một trong những nguyên nhân hàng đầu dẫn tới lây nhiễm bệnh sùi mào gà - một căn bệnh xã hội nguy hại. Sùi mào gà là bệnh do virus HPV (Human Papilloma virus) gây ra, triệu chứng điển hình của bệnh đó là các tổn thương sùi tại vị trí nhiễm bệnh, ngoài bộ phận sinh dục thì sùi mào gà hậu môn cũng là tình trạng thường gặp ở nhiều trường hợp.

The stomach flu is the second most common disease met in American family and causes about 50,000 hospitalizations per year. The virus can be transferred from food of infected person and spread from one person to another through plate, food, and water which made this virus highly spread and disease can be happened if you lazy to wash your hand or do sterilization in Public facility.

H1N1 or swine flu is a human respiratory infection caused by the virus. It spreads from human to human. Some symptoms and prevention of swine flu are…..

Viêm cổ tử cung là tình trạng viêm nhiễm đường sinh dục dưới hay gặp ở phụ nữ trong độ tuổi sinh đẻ. Nguyên nhân thường do lậu cầu, xoắn khuẩn giang mai, vi khuẩn gây bệnh hạ cam, Chlamydia trachomatis, herpes simplesx virus, HPV (human papilloma virus), Trichomonas hoặc do tiếp xúc (giao hợp sâu, thô bạo, đặt băng vệ sinh trong âm đạo, hóa chất xịt rửa…).

Infection with the Nipah (NiV) virus has recently stormed the entire nation and continues to do so. He claimed more than two dozen lives in India and new cases are identified.

The market is broadly segmented into instruments, assays & kits, and services & software based on the basis of products & services. The assays & kits segment is expected to account for the largest share of the global POC molecular diagnostics market. This segment is also projected to register the highest CAGR during the forecast period. Based on the applications, the market is segmented into respiratory diseases, hospital-acquired infections (HAIs), sexually transmitted diseases (STDs), oncology, hepatitis, and other applications (meningococcal meningitis, malaria, Herpes Simplex Virus, Ebola, Zika virus).

Have you hear about "Coronavirus" that increase their virus day by day? If yes so you should know more about this kind of such an dangerous virus that effects all kind of age, gender and area's very fastly. If you don't aware about this virus so you must be read out this blog here!

Velpanat 400Mg Suppliers Price India, , we are leading suppliers and exporters of velpanat 400mg (Velpatasvir and Sofosbuvir) tablets in China, Russia, Hongkong, India. Modern times medicine provide the best price on Velpanat 400 Mg tablet which you can- not buy from other venders. As a leading suppliers we ensure our customers that we are commited to on-time deliverly of the product that you buy from us. We are leading suppliers & exporters of "Velpanat 400Mg" in China, Russia, Hongkong, Bulgaria, Romania, India, Uk, USA. We're largest suppliers of Natco medicines & provide you the best price on Velpanat. The lowest price sellers, suppliers, distributors & Exporters from Delhi. For more info please contact us. Online Velpanat 400Mg tablet suppliers in India Velpanat 400Mg Suppliers India, Velpanat 400Mg Suppliers Russia, Velpanat tablet is a fixed-dose combination tablet containing sofosbuvir and velpatasvir for oral administration which are direct-acting antiviral agents against the hepatits C virus. Sofosbuvir is a nucleotide analog HCV NS5B polymerase inhibitor and velpatasvir is an NS5A inhibitor. Velpanat-tablet contains 400 mg of sofosbuvir and 100 mg of velpatasvir 100mg each tablets. the each tablet of it include the following inactive ingredients:copovidone, croscarmellose sodium, magnesium stearate, and microcrystalline cellulose. Film coated of velpanat medicine each tablet- sofosbuvir 400 mg and ledipasvir 90 mg with a coating material containing the following inactive ingredients: Titanium Dioxide IP and Brilliant blue FCF, polyethylene glycol, polyvinyl alcohol and titanium dioxide. The effect of sofosbuvir 400 mg (recommended dosage) and 1200 mg (three times the recommended dosage) on QTc interval was evaluted in an active-controlled (moxifloxacin 400 mg) thorough QT trial. Buy Online Suppliers price of Velpanat 400Mg India Details of velpanat tablet- Brand name - Velpanat Tablets Generic of medicine - Velpatasvir and Sofsob

A virus naturally carried by wild birds causes avian flu, more popularly known as "bird flu," (Jan 2007). The Avian Flu virus is an influenza virus of type A. Influenza viruses of type A can be found in human beings, birds and other mammals. This is the only form of influenza virus in history that has caused pandemics (Beigel, 2008).

Future pandemics could be even more lethal than Covid-19 so the lessons learned from the outbreak must not be squandered and the world must ensure it is prepared for the next viral onslaught, one of the creators of the Oxford-AstraZeneca vaccine said. "The truth is, the next one could be worse. It could be more contagious, or more lethal, or both," Prof Dame Sarah Gilbert said in the Richard Dimbleby Lecture, the BBC reported. "This will not be the last time a virus threatens our lives and our livelihoods." Gilbert, a professor of vaccinology at the University of Oxford, said the world should make sure it is better prepared for the next virus. "The advances we have made, and the knowledge we have gained, must not be lost," she said. Efforts to end the Covid-19 pandemic have been uneven and fragmented, marked by limited access to vaccines in low-income countries while the "healthy and wealthy" in rich countries get boosters, health experts say.

Britain has approved a new coronavirus vaccine by the Austrian-French drugmaker Valneva. "An approval has been granted after the Valneva Covid-19 vaccine was found to meet the required safety, quality and effectiveness standards," the Medicines and Healthcare products Regulatory Agency said in a statement on Thursday (April 14), adding: "It is also the first, whole-virus inactivated Covid-19 vaccine to gain regulatory approval in the UK." In vaccines such as Valneva's VLA2001, the virus is grown in a lab and then made completely inactive so that it cannot infect cells or replicate in the body but can still trigger an immune response. It is seen by some as having the potential to win over people wary of some which use new mRNA technology. Valneva CEO Thomas Lingelbach said that "this authorisation could pave the way for the availability of an alternative vaccine solution for the UK population."

Johnson & Johnson said on Wednesday (January 18) that it was pulling the plug on a late-stage global trial of an HIV vaccine after the shot was found ineffective at preventing infections. The failure of the trial marks yet another setback in the search for a vaccine against a virus known to mutate rapidly and find unique ways to evade the immune system, and comes more than a year after another of J&J's HIV vaccine failed a study. "It's not the outcome we had hoped for, unfortunately," said a spokesperson for the National Institute of Allergy and Infectious Diseases, a J&J partner in the trial. "The development of a safe and effective HIV vaccine has been a considerable scientific challenge, but we will learn from this study and continue forward." The trial involved administering two different types of a shot, which uses a cold-causing virus to deliver the genetic code of HIV, spread over four vaccination visits in a year. J&J used similar technology for its COVID-19 vaccine. The study, which began in 2019, was conducted at over 50 sites and included about 3,900 gay men and transgender people - groups that are considered vulnerable to the infection.